Form D · Biotechnology
Quiver Holdings Inc.
Cambridge, MA · CIK 0002160800
Offering snapshot reported Oct 21, 2026 · SEC filing
- Reported sold
- $3.01M Indefinite offering
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 8, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 21, 2026 | Initial | $3,005,000 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-601971
Convertible notes with warrant coverage of 70% of principal.
Source: Form D, filed Oct 21, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Paul Black | Director |
| Graham T Dempsey | Executive |
| Jonathan Fleming | Director |
| Janet Foutty | Director |
| David Liederbach | Executive |
| David Margulies | Director, Executive |
| Paul Roma | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
150 Cambridgepark Drive 5th Floor
Cambridge, MA, 02140
Phone: 6173963611
Cambridge, MA, 02140
Phone: 6173963611